Table 2. Clinical and laboratory parameters during the study coursea
Week
Candesartan, 32 mg(n = 15)
Candesartan, 64 mg(n = 17)
P
Systolic BP (mmHg)
run-in
0
136 ± 13
135 ± 17
NS
first 16 mg candesartan
4
132 ± 20
137 ± 20
NS
high-dose candesartan
16
132 ± 15
130 ± 21b
NS
second 16 mg candesartan
20
129 ± 12
131 ± 13
NS
Diastolic BP (mmHg)
run-in
0
84 ± 9
85 ± 7
NS
first 16 mg candesartan
4
85 ± 14
85 ± 9
NS
high-dose candesartan
16
85 ± 11
80 ± 11b,c
NS
second 16 mg candesartan
20
83 ± 10
83 ± 8
NS
Creatinine clearance (ml/min)
run-in
0
96 ± 38
106 ± 65
NS
first 16 mg candesartan
4
98 ± 42
107 ± 68
NS
high-dose candesartan
16
97 ± 48
98 ± 63
NS
second 16 mg candesartan
20
94 ± 52
102 ± 66
NS
Urinary sodium excretion (mol/d)
run-in
0
218 ± 93
286 ± 112
NS
first 16 mg candesartan
4
221 ± 93
245 ± 101d
NS
high-dose candesartan
16
255 ± 83
236 ± 103c
NS
second 16 mg candesartan
20
235 ± 97
249 ± 98
NS
a All data are expressed as mean ± SD. P values in the table are given for comparison between treatment groups (t test). Within groups the following analyses were performed and are highlighted by superscript letters (one symbol: P < 0.05; two symbols: P < 0.01):
b high-dose candesartan phase versus first 16 mg candesartan phase;
c high-dose candesartan phase versus run-in phase;
d first 16 mg candesartan phase versus run-in phase.
